A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer
Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation
therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours
d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min
weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5
mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
tumor response rate
Response was analyzed according to the RECIST system, based on CT scans.
1 month after treatment.
Shenglin Ma, MD
Zhejiang Cancer Hospital
China: Ethics Committee